No Data
No Data
No Data
No Data
No Data
Wolf Popper LLP Continues Its Investigation on Behalf of Investors in Harmony Biosciences Holdings, Inc.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing to investigate potential securities fraud claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony") common stock
GlobeNewswireApr 25 19:00
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30,
PR NewswireApr 16 20:05
Piper Sandler Remains a Buy on Harmony Biosciences Holdings (HRMY)
TipRanksApr 12 20:30
Needham: Reiterates Harmony Biosciences (HRMY.US) rating, adjusted from buy to buy rating, target price of $50.00.
Needham: Reiterates Harmony Biosciences (HRMY.US) rating, adjusted from buy to buy rating, target price of $50.00.
Zhitong FinanceApr 12 01:31
Harmony Inks Licensing Deal for Sleep Disorder Therapy
Seeking AlphaApr 12 00:36
Harmony Biosciences Holdings (HRMY) Gets a Sell From Goldman Sachs
TipRanksApr 11 22:45
No Data
No Data